Gemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer

dc.creatorJiménez Fonseca, P.
dc.creatorSolis, M. P.
dc.creatorGarrido, Marcelo
dc.creatorFaez, L.
dc.creatorRodriguez, D.
dc.creatorRuiz, A. L.
dc.creatorSánchez Lorenzo, M.L.
dc.creatorUriol, E.
dc.creatorDolores Menéndez, María
dc.creatorViéitez de Prado, José María
dc.date.accessioned2020-09-03T04:58:44Z
dc.date.accessioned2020-09-25T13:52:47Z
dc.date.available2020-09-03T04:58:44Z
dc.date.available2020-09-25T13:52:47Z
dc.date.created2020-09-03T04:58:44Z
dc.date.issued2015
dc.identifier1699-048X
dc.identifierhttps://doi.org/10.1007/s12094-014-1243-1
dc.identifierhttps://repositorio.uc.cl/handle/11534/43417
dc.identifier10.1007/s12094-014-1243-1
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3286263
dc.languageen
dc.subjectRefractory metastatic colorectal cancer
dc.subjectGemcitabine
dc.subjectCapecitabine
dc.subjectThird-line chemotherapy
dc.subjectProgression-free survival
dc.subjectOverall survival
dc.titleGemcitabine plus capecitabine (Gem–Cape) biweekly in chemorefractory metastatic colorectal cancer
dc.typeArtículo


Este ítem pertenece a la siguiente institución